Targeting ECM-producing cells with CAR-T therapy alleviates fibrosis in chronic kidney disease
Cell Stem Cell · 2025-09 · 32 (9) · 1390-1402.e9
DOI: 10.1016/j.stem.2025.07.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Stem Cell, 2025-09. Verfasst von Songbo Zhao und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, The Key Laboratory of Infection and Immunity of Shandong Province, School of Basic Medical Sciences, Shandong University,…. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Extracellular Matrix, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shandong Province Natural Science Foundation.
Abstract (Originalsprache)
Kidney fibrosis is a hallmark of chronic kidney disease (CKD) and a potential therapeutic target. However, clinical interventions and therapies targeting kidney fibrosis remain conceptual and practical challenges due to the complex origin, functional heterogeneity, and regulation of scar-forming cells. Here, we define fibroblasts, pericytes, and myofibroblasts as the major extracellular matrix (ECM)-producing cells in the kidney, highlighting their primary contribution to kidney fibrosis. We then identify platelet-derived growth factor receptor β (PDGFRβ) as a potential targeting surface antigen for anti-fibrotic chimeric antigen receptor (CAR)-T against CKD. In multiple mouse CKD models, both adoptive transfer and CD5-lipid nanoparticle (LNP)-mediated in vivo generation of PDGFRβ CAR-T cells significantly ameliorate fibrosis-associated pathologies, including kidney, myocardial interstitial, and perivascular fibrosis without notable toxicity, evoking an integrated therapeutic strategy for multi-organ fibrosis in mice with CKD and its cardiovascular complications. The anti-fibrotic effects are also demonstrated in the human kidney organoid CKD, further strongly supporting the therapeutic potential for the treatment of patients with CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, The Key Laboratory of Infection and Immunity of Shandong Province, School of Basic Medical Sciences, Shandong University, Jinan 250012, China.
- Department of Hematology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan 250012, China.
- Department of Pharmaceutics, NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong Universit…
- Division of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
- Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
- Renal Division, Key Laboratory of Renal Disease, Ministry of Health of China, Peking University Institute of Nephrology, Peking University First Hospital, Key Laboratory of Chronic Kidney Disease Prevention and Treatmen…
Förderung
- National Natural Science Foundation of China
- Shandong Province Natural Science Foundation
Zitieren
APA
Zhao, S., Li, R., Xia, Y., Wang, X., Liu, Z., Chu, Q., He, J., Zhang, J., Guo, Y., Wang, Y., Wu, J., Zhang, Y., Wang, Z., Zhang, Z., Zeng, R., Zhang, C., Lv, J., Sun, J., Tang, W., & Yi, F. (2025). Targeting ECM-producing cells with CAR-T therapy alleviates fibrosis in chronic kidney disease. Cell Stem Cell, 32(9), 1390-1402.e9. https://doi.org/10.1016/j.stem.2025.07.014
Vancouver
Zhao S, Li R, Xia Y, Wang X, Liu Z, Chu Q, et al. Targeting ECM-producing cells with CAR-T therapy alleviates fibrosis in chronic kidney disease. Cell Stem Cell. 2025;32(9):1390-1402.e9. doi:10.1016/j.stem.2025.07.014
BibTeX
@article{Zhao2025,
author = {Zhao, Songbo and Li, Rongkun and Xia, Yuan and Wang, Xiaojie and Liu, Zhiyong and Chu, Qingqing and He, Jiman and Zhang, Jiaying and Guo, Yixuan and Wang, Youzhao and Wu, Jichao and Zhang, Yan and Wang, Ziying and Zhang, Zhiyue and Zeng, Rui and Zhang, Chun and Lv, Jicheng and Sun, Jinpeng and Tang, Wei and Yi, Fan},
title = {Targeting ECM-producing cells with CAR-T therapy alleviates fibrosis in chronic kidney disease},
journal = {Cell Stem Cell},
year = {2025},
volume = {32},
number = {9},
pages = {1390--1402.e9},
doi = {10.1016/j.stem.2025.07.014}
}
EUVIMED